Kristi Rosa | Authors


Zenocutuzumab Effectively Blocks Growth of NRG1 Fusion-Driven Tumors

April 10, 2021

In NRG1 fusion–positive cell lines, zenocutuzumab demonstrated blockage of growth and cell death, as well as tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.

OS Benefit Suggested for Frontline IO Versus TKIs in Metastatic Non–Clear Cell RCC

February 11, 2021

A retrospective study has suggested that immunotherapy may have a great survival benefit in the frontline setting for patients with metastatic non–clear cell renal cell carcinoma (RCC) than select targeted therapies.

Beti-Cel Shows Good Activity in Transfusion-Dependent Children With Beta-Thalassemia

February 10, 2021

Results from 2 phase 3 clinical trials showed that use of the investigational gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients under the age of 18 years with transfusion-dependent beta-thalassemia.